Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.38 |
| ▸ | CCND1 | P24385 | 2/20 | 0.38 |
| ▸ | CCND2 | P30279 | 2/20 | 0.38 |
| ▸ | CCND3 | P30281 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096336 | 1.00 | CA12 (0.46) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL4098781 | 0.86 | KAT2B (0.47) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL4098785 | 0.86 | KAT2B (0.47) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL18926939 | 0.83 | CA12 (0.52) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL4090137 | 0.74 | KMT2A (0.39) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL4090134 | 0.74 | KMT2A (0.39) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL3441071 | 0.74 | CA12 (0.57) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL29757375 | 0.74 | CA12 (0.57) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL29941396 | 0.74 | CA12 (0.53) | CA12BRD4BRPF1CA9KAT2B | |
| SCHEMBL7128827 | 0.74 | CA12 (0.53) | CA12BRD4BRPF1CA9KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522906-B2 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140221364-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8680115-B2 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20090239903-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-7576078-B2 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576100-B2 | Muscarinic agonists | ACADIA PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7550459-B2 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | ACADIA PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7307075-B2 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1828176-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060199810-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| US-20060199813-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006068904-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| EP-1461318-B9 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | ACADIA PHARMACEUTICALS INC. | 2005-09-22 | — | — | US | disclosed |
| EP-1461318-B1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1461318-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003057672-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199813-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | CA12 2550/4885BRD4 327/4885BRPF1 1705/4885 |
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | CHRNA4, CHRNA2, CHRNA5 | CA12 4227/4885BRD4 398/4885BRPF1 2024/4885 |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | CA12 2550/4885BRD4 327/4885BRPF1 1705/4885 |
| US-20140221364-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | CHRM3, CHRM5, CHRM2 | CA12 2550/4885BRD4 327/4885BRPF1 1705/4885 |
| US-20090239903-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | CHRM3, CHRM5, CHRM2 | CA12 2550/4885BRD4 327/4885BRPF1 1705/4885 |
| US-20060199810-A1 | Muscarinic agonists | CHRM3, CHRM5, CHRM2 | CA12 2118/4885BRD4 487/4885BRPF1 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.